Viloxazine HCl in the treatment of endogenous depression: A standard (imipramine) controlled clinical study

J. P. Mcevoy, J. Libiger, W. H. Wilson, T. A. Ban, S. Berney, W. Guy

Research output: Contribution to journalArticle

2 Scopus citations


In a four week, double-blind clinical trial, 20 patients with endogenous depression were randomly assigned to treatment with either viloxazine or imipramine. Statistically significant improvement was observed on the Hamilton Psychiatric Rating Scales for Depression and Anxiety for both treatment groups. There were no differences between the two treatment groups in the type, incidence, or severity of treatment emergent symptoms. No medication-related abnormalities in clinical laboratory values occurred in either treatment group.

Original languageEnglish (US)
Pages (from-to)111-112
Number of pages2
JournalJournal of Clinical Psychiatry
Issue number3
Publication statusPublished - May 5 1982
Externally publishedYes


ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this